Cargando…
Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages
Systemic sclerosis (SSc) is a recalcitrant autoimmune disease for which there is no cure. Mesenchymal stem cell (MSC)-based treatment has emerged as a promising therapeutic option for several autoimmune diseases. Previously, we found that the immunoregulatory potential of MSCs can be greatly enhance...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701228/ https://www.ncbi.nlm.nih.gov/pubmed/36435837 http://dx.doi.org/10.1038/s41420-022-01264-2 |
_version_ | 1784839493943033856 |
---|---|
author | Gong, Pixia Ding, Yayun Sun, Rongrong Jiang, Zishan Li, Wen Su, Xiao Tian, Ruifeng Zhou, Yipeng Wang, Tingting Jiang, Junjie Li, Peishan Shao, Changshun Shi, Yufang |
author_facet | Gong, Pixia Ding, Yayun Sun, Rongrong Jiang, Zishan Li, Wen Su, Xiao Tian, Ruifeng Zhou, Yipeng Wang, Tingting Jiang, Junjie Li, Peishan Shao, Changshun Shi, Yufang |
author_sort | Gong, Pixia |
collection | PubMed |
description | Systemic sclerosis (SSc) is a recalcitrant autoimmune disease for which there is no cure. Mesenchymal stem cell (MSC)-based treatment has emerged as a promising therapeutic option for several autoimmune diseases. Previously, we found that the immunoregulatory potential of MSCs can be greatly enhanced by IFN-γ and TNF-α. Here, we found that IFN-γ- and TNF-α-pretreated MSCs significantly alleviated skin fibrosis in a bleomycin (BLM)-induced SSc model. Macrophages were found to be the predominant profibrotic immune cell population in the pathogenesis of SSc. The accumulation of macrophages was significantly decreased by MSC treatment. Importantly, MSCs primarily reduced the population of maturing macrophages with high CCR2 expression by inhibiting the generation of CCL2 from fibroblasts and macrophages. This finding may help to improve MSC-based clinical treatments for SSc patients. |
format | Online Article Text |
id | pubmed-9701228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-97012282022-11-28 Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages Gong, Pixia Ding, Yayun Sun, Rongrong Jiang, Zishan Li, Wen Su, Xiao Tian, Ruifeng Zhou, Yipeng Wang, Tingting Jiang, Junjie Li, Peishan Shao, Changshun Shi, Yufang Cell Death Discov Article Systemic sclerosis (SSc) is a recalcitrant autoimmune disease for which there is no cure. Mesenchymal stem cell (MSC)-based treatment has emerged as a promising therapeutic option for several autoimmune diseases. Previously, we found that the immunoregulatory potential of MSCs can be greatly enhanced by IFN-γ and TNF-α. Here, we found that IFN-γ- and TNF-α-pretreated MSCs significantly alleviated skin fibrosis in a bleomycin (BLM)-induced SSc model. Macrophages were found to be the predominant profibrotic immune cell population in the pathogenesis of SSc. The accumulation of macrophages was significantly decreased by MSC treatment. Importantly, MSCs primarily reduced the population of maturing macrophages with high CCR2 expression by inhibiting the generation of CCL2 from fibroblasts and macrophages. This finding may help to improve MSC-based clinical treatments for SSc patients. Nature Publishing Group UK 2022-11-26 /pmc/articles/PMC9701228/ /pubmed/36435837 http://dx.doi.org/10.1038/s41420-022-01264-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Gong, Pixia Ding, Yayun Sun, Rongrong Jiang, Zishan Li, Wen Su, Xiao Tian, Ruifeng Zhou, Yipeng Wang, Tingting Jiang, Junjie Li, Peishan Shao, Changshun Shi, Yufang Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages |
title | Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages |
title_full | Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages |
title_fullStr | Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages |
title_full_unstemmed | Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages |
title_short | Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages |
title_sort | mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701228/ https://www.ncbi.nlm.nih.gov/pubmed/36435837 http://dx.doi.org/10.1038/s41420-022-01264-2 |
work_keys_str_mv | AT gongpixia mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT dingyayun mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT sunrongrong mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT jiangzishan mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT liwen mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT suxiao mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT tianruifeng mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT zhouyipeng mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT wangtingting mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT jiangjunjie mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT lipeishan mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT shaochangshun mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages AT shiyufang mesenchymalstemcellsalleviatesystemicsclerosisbyinhibitingtherecruitmentofpathogenicmacrophages |